By Colin Kellaher Regeneron Pharmaceuticals on Monday said the U.S. Food and Drug Administration has turned away its application seeking approval of odronextamab to treat the two most common.
Shares of Regeneron were down over 2% in premarket trading. Eylea, jointly developed with Bayer AG, has driven Regeneron's earnings for years, but sales have now come under pressure, partly from Roche's Vabysmo that secured U.S. approval in 2022. Regeneron has set its hopes on a higher-dose version of Eylea.
Regeneron Pharmaceuticals on
Thursday beat Wall Street estimates for third-quarter profit,
driven by strong demand for its eczema treatment Dupixent. On an adjusted basis, the company.
Regeneron Pharmaceuticals on
Tuesday said it had entered into a contract worth $326 million
with a U.S. government agency for the development of
next-generation antibody therapy for COVID-19.